Daily Stock List
Oculus VisionTech, Inc. (OVTZ)
UltimatePennyStock reported previously on Oculus VisionTech, Inc. (OVTZ), and today we report on the Company, here at the QualityStocks Daily Newsletter.
OTCQB-listed Oculus VisionTech, Inc. designs and markets technology for the delivery of digital media. It developed its MediaEscort, MediaSentinel, and SmartMark digital watermarking products and technologies to provide a forceful means for producers and distributors to invisibly protect their content. Oculus VisionTech is headquartered in Vancouver, British Columbia.
The Company's systems, services, and delivery solutions include digital watermark solutions and video content production, content encoding, media asset management, and media and application hosting. In addition, it includes multi-mode content distribution, transaction data capture and reporting, e-commerce, specialized engineering services, and Internet streaming hardware.
The foundation of Oculus VisionTech's products and services are on its media delivery infrastructure and software. It has developed a number of specific products and services. These include the above-mentioned MediaSentinel and SmartMarks, a process that watermarks digital video content.
SmartMarks™ are invisible, unremovable, imperceptible forensic "digital watermarks". These are embedded within every video frame to protect digital video from piracy. SmartMarks™ work with existing production and distribution technology to protect copyrighted material without requiring new equipment in the distribution or playback environment. SmartMarks™ give enforcement agencies the proof they require to halt piracy.
Services include StreamHQ, a collection of source-to-destination media delivery services marketed to businesses; and EncodeHQ, a service that digitizes and compresses analog-source video. Furthermore, services include hardware server and encoder system applications under the brand name Hurricane Mediacaster; ZMail, a service that delivers Web and rich media content to targeted audiences, and mediaClix, a service that delivers content similar to Zmail, however, originating from an existing Web presence.
Oculus VisionTech’s near-term business objectives include patenting and licensing new technology developed within the corporate R&D program; and attaining industry recognition for the premier architectural, functional, and business differentiators of its MediaSentinel architecture.
Additionally, near-term objectives include demonstrating proof of concept on a commercial project with MediaSentinel architecture; establishing StreamHQ as the industry standard in the streaming video and rich media marketplace; and expanding StreamHQ functionality to provide enhanced support for corporate training and education markets.
Oculus VisionTech received notice that its sole Software License Agreement dated November 13, 2006 for customized deployment of its proprietary watermarking technology to one of the industry's major Hollywood studios was terminated, effective January 31, 2015.
The Company is still active in R&D. It continues to concentrate on refining, enhancing, and marketing its stable of product offerings. This includes MediaSentinel, MediaEscort, and SmartMarks, to help the entertainment industry, particularly in film and television.
Oculus VisionTech, Inc. (OVTZ), closed Tuesday's trading session at $0.12, up 33.33%, on 806 volume with 2 trades. The average volume for the last 60 days is 17,081 and the stock's 52-week low/high is $0.055/$0.25.
MRI Interventions, Inc. (MRIC)
Wall Street Resources reported previously on MRI Interventions, Inc. (MRIC), and we are highlighting the Company today, here at the QualityStocks Daily Newsletter.
OTC Bulletin Board-listed MRI Interventions, Inc. is a medical device company. It develops and commercializes distinct platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging, or MRI, guidance. Using a hospital's existing MRI suite, the design of its FDA-cleared and CE-marked ClearPoint® system is to enable a range of minimally invasive procedures in the brain. MRI Interventions has its headquarters in Irvine, California.
ClearPoint® is an integrated system of hardware components, disposable components, and intuitive, menu-driven software. MRI Interventions has a co-development and co-distribution agreement with Brainlab, a leader in software-driven medical technology, relating to the ClearPoint® system. Additionally, the Company is working with Boston Scientific to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications.
The ClearPoint® system enables real-time MRI-guided navigation for a broad variety of minimally-invasive neurosurgery procedures. The platform is especially well-suited for facilitating drug delivery directly to brain tumors. The ClearPoint® system provides MRI-based stereotactic guidance for the placement and operation of instruments or devices during the planning and operation of neurological procedures performed within the MRI suite. ClearPoint® procedures can be used with 1.5T and 3T scanners.
The ClearPoint® system is the only navigation platform designed to allow real-time visualization during minimally-invasive neurosurgical procedures. ClearPoint software works with MRI to assist surgeons in planning a target and trajectory; the SmartFrame® targeting devices enable the MRI-guided alignment and minimally invasive insertion of surgical instruments.
Furthermore, MRI Interventions is developing the ClearTrace® system in partnership with Siemens Healthcare. This is to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation.
Last week, MRI Interventions announced that its ClearPoint® neuro navigation platform will be on exhibit at the 2015 Annual Meeting of the American Association of Neurological Surgeons (AANS) May 4-6, 2015, in Washington, D.C. The Company said that Conference attendees are invited to visit the MRI Interventions booth (#708) to learn about the ClearPoint® system's unique capability to enable a broad spectrum of neurosurgical procedures under real-time MRI guidance.
MRI Interventions, Inc. (MRIC), closed Tuesday's trading session at $1.227, up 6.70%, on 196,070 volume with 151 trades. The average volume for the last 60 days is 101,442 and the stock's 52-week low/high is $0.652/$1.3401.
White Mountain Titanium Corp. (WMTM)
MoneyTV and Penny Stock Chaser reported previously on White Mountain Titanium Corp. (WMTM), and today we highlight the Company, here at the QualityStocks Daily Newsletter.
White Mountain Titanium Corp. is a mineral exploration company that engages in the search for mineral deposits or reserves that could be economically and legally extracted or recovered. It holds mining concessions encompassing two rutile properties located in the Atacama region (Region III) of northern Chile, specifically Cerro Blanco and the newly discovered La Martina.
The Company’s primary business is to explore for and develop natural rutile deposits on its mining concessions. Additionally, it plans to expand its exploration activities on the La Martina concessions which it discovered in 2013. White Mountain Titanium is headquartered in Santiago, Chile and the Company’s shares trade on the OTC Markets Group’s OTCQB.
White Mountain Titanium holds mining concessions on the Cerro Blanco property. The property consists of 41 registered mining exploitation concessions and 34 mining exploration concessions in the process of being constituted, over roughly 17,041 hectares located approximately 39 kilometres west of the City of Vallenar in the Atacama, or Region III, geographic region of northern Chile.
White Mountain Titanium has six wholly-owned subsidiaries. These include SCM White Mountain Titanium, a Chilean stock company which holds its Chilean mining concessions for its Cerro Blanco project and conducts its principal exploration operations on that property; White Mountain Metals SpA, a Chilean stock company that currently has no active operations; and White Mountain Titanium Corp., a Canadian stock company that provides management and administrative services on behalf of the U.S. parent.
Wholly-owned subsidiaries also include White Mountain Minerals SpA, which holds its Chilean mining concessions for its La Martina project and conducts its main exploration operations on that property; White Mountain Energy Ltda., an inactive Chilean company; and White Mountain Titanium (Hong Kong), a Hong Kong company which has been recently re-activated and is intended to be the holding company for White Mountain Titanium’s operations in the PRC.
White Mountain Titanium continues to fund R&D on the Chinuka Process, which is conducting research into the recovery of feldspar and the production of refined titanium metal from materials sourced from these mining concessions. Work continues to investigate the commercial viability of producing a feldspar co-product. The Company indicates that feldspar could find applications in the glass and ceramics industries.
White Mountain Titanium’s primary goal is to complete its EIS application and secure the Second Tranche funding. If achieved, its plan is to advance the Cerro Blanco project towards a final engineering feasibility, to secure off-take agreements for the planned rutile concentrate output, and to secure funding or other arrangements to place the project into production, if warranted. The Company’s plan would be to sell the rutile concentrate to titanium metal and pigment producers.
White Mountain Titanium Corp. (WMTM), closed Tuesday's trading session at $0.3749, up 7.42%, on 28,550 volume with 10 trades. The average volume for the last 60 days is 26,234 and the stock's 52-week low/high is $0.188/$0.58.
SITO Mobile Ltd. (SITO)
TaglichBrothers, PennyStocks24, and BUYINS.NET reported recently on SITO Mobile Ltd. (SITO), and we are highlighting the Company as well, here at the QualityStocks Daily Newsletter.
SITO Mobile Ltd. is a leading mobile media solutions provider listed on the OTC Bulletin Board. The Company serves businesses, advertisers, and brands. Its solution, via patented technologies and a user-friendly platform, enables marketers to create content targeted to key audiences, based on location, interests, behaviors, and loyalty. SITO Mobile is based in Jersey City, New Jersey.
On September 29, 2014, Single Touch Systems, Inc. (SITO), revealed its new name and brand - SITO Mobile. The rebranding follows a period of expansion for the Company across the United States and Canada. The new corporate identity underpins SITO Mobile's concentration on mobile location-based advertising and mobile messaging platforms. These give brands, agencies, and retailers the power to transform digital marketing through delivering targeted mobile advertising campaigns based on geo-location, in-store traffic, and customer response.
Through the increase of mobile devices, SITO Mobile empowers its customers to deliver actionable content in a real-time manner. This drives action and engagement from consumers, while providing vital measurement and analytics, which allow campaigns to be fluid and transaction driven.
SITO Mobile announced in October 2014 a partnership through which Health Media Network (HMN) will leverage SITO Mobile's mobile media platform to fuel a national location-based advertising network within physician offices nationally. HMN helps to improve the communication between doctor and patient, with the aim of improving healthcare outcomes. HMN will use SITO Mobile's location-based mobile advertising platform as an extension of its existing targeted digital media capabilities. HMN is one of the country’s fastest growing digital Point of Care media enterprises.
The platform presents the opportunity for health marketers to engage with consumers actively discussing treatment options with their doctors. In addition, it offers the ability to reconnect with patients as they travel to the pharmacy or other retailer to fulfill prescriptions, buy OTC (Over-the-Counter) products, and/or interact with the pharmacist.
This month, SITO Mobile announced that it launched Version 1.0 of its self-serve campaign management platform for the small and mid-sized business market. It released a case study, which details the pilot results following a successful 14-store, 12-week campaign managed by a regional food retailer. The campaign included sending private label and co-sponsored mobile-only coupons and incentives to segmented customer groups by way of text messages.
The goals of the pilot were to use mobile as a communication channel to increase in-store traffic and achieve product lift of promoted items. Consequently, the campaign averaged a 30 percent month-over-month increase in the number of consumers choosing to receive SMS messages and a 49 percent coupon redemption rate at the point of sales.
SITO Mobile Ltd. (SITO), closed Tuesday's trading session at $0.318, up 1.68%, on 188,067 volume with 38 trades. The average volume for the last 60 days is 141,218 and the stock's 52-week low/high is $0.1475/$0.505.
Monarch America, Inc. (BTFL)
StreetAuthority Financial, Insider Wealth Alert, Trade of the Week, and Investors Alley reported recently on Monarch America, Inc. (BTFL), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Listed on the OTCQB, Monarch America, Inc.’s mission and vision is to be recognized as one of the nation’s premier, fully integrated cannabis management enterprises. It offers complete back office, management, product development and staffing solutions for retail dispensaries. The Company also offers national branding awareness and vertical integration. Monarch America works to make each new client a strong competitor in its market. The Company is headquartered in Denver, Colorado.
Concerning Monarch America’s brands, its MFuze™ is a Trademark, Domain and Service Mark owned by the Company. The creation of MFuzed™ was to provide a licensed brand, permitting entities to license the Mfuze name and to design, develop and manufacture proprietary lines of marijuana infused beverage product.
Additionally, HBH Industries Inc. is a wholly-owned subsidiary of Monarch America. HBH will specialize in cultivation facility leasing, property management, and equipment leasing to the medical and recreational marijuana sector.
Monarch America has completed the acquisition of The Big Tomato, Inc. which is an established Denver area store, warehouse distribution facility, and hydroponics and indoor garden supplier. Subsequent to the completion of the merger agreement, The Big Tomato is a wholly-owned subsidiary of Monarch America. The Big Tomato is a top supplier of hydroponics & indoor gardening supplies for Denver, Colorado and the surrounding communities.
On the whole, Monarch America expects to garner income through providing its management and consulting services to its clients cultivation facilities and retail dispensaries. In addition, it expects to benefit from the licensing of its proprietary branded infused product lines and the sales from The Big Tomato.
Last month, Monarch America announced that it entered into an Exclusive Distribution Agreement with Colorado Business Associates LLC, the exclusive owner of a group of proprietary products called MiraClays. MiraClays is microscopic crystalline calcium clay. It is rich in more than 70 other minerals and trace elements. When used in the agricultural industry, 100 percent natural MiraClays can be applied directly onto the growing medium or mix in water. The Exclusive Distribution Agreement appoints Monarch America as the exclusive distributor of MiraClays products for the agricultural industry in the U.S. and Canada.
Monarch America, Inc. (BTFL), closed Tuesday's trading session at $0.124, up 13.76%, on 1,228,146 volume with 242 trades. The average volume for the last 60 days is 219,613 and the stock's 52-week low/high is $0.0551/$1.33.
KollagenX Corp. (KGNX)
Today we choose to report on KollagenX Corp. (KGNX), here at the QualityStocks Daily Newsletter.
KollagenX Corp. is an advanced skin care development and marketing enterprise. The Company’s principal emphasis is nano gold technology, also called NGT®. Mr. Rondell Fletcher and Mr. George Huerta established KollagenX® in early 2008. KollagenX® develops and introduces new, safe, more affordable eco-friendly NGT® products that the Company believes will help improve the quality of lives.
OTCQB-listed KollagenX has its corporate head office in Chino Hills, California. Founded in 2007, the Company previously went by the name Integrated Electric Systems Corp. It changed its name to KollagenX Corp. in July of 2014.
KollagenX® helps bring the nourishment one’s skin requires to be healthier and function more effectively. The Company indicates that its innovative anti-aging skin care products restore a natural youthful glow and a smoother, suppler appearance.
KollagenX® Nano Gold Technology (NGT®) has recognition for its ability to ward off UV damage, tighten lax skin, as well as reduce the appearance of discoloration spotted skin. This is in addition to its antioxidant and antimicrobial abilities. KollagenX® (NGT®) promotes increased circulation, assists in eliminating toxins from the body, and hastens tissue repair. It promotes the growth of the skin cells through replacing the aging cells for revitalization.
KollagenX’s Collection includes 24KT Gold Face Mask, 24KT Gold Under-Eye’s, 24KT Gold Eye Serum, 24KT Gold Hydrating Cream, 24KT Gold Cleanser, and 24KT Gold Lip Gloss. KollagenX Nano Gold is 99.999 percent pure gold, and is free of any hazardous metal elements. In addition, it is 1/2000 the size of an average pore, therefore easily penetrating into the dermis.
Recently, KollagenX showcased its complete lineup of skin care products at the 13th annual International Esthetics, Cosmetics and Spa Conference. This year's event took place on March 8-10, 2015, at the Javits Convention Center in New York, New York. This Conference is the largest spa and wellness show on the East Coast.
This month, KollagenX® announced that it received approval for their 24KT Nano Gold product line from the Ministry of Health of Kuwait. Approval was granted to import product to Kuwait.
KollagenX Corp. (KGNX), closed Tuesday's trading session at $0.61, up 10.91%, on 333,859 volume with 120 trades. The average volume for the last 60 days is 7,727 and the stock's 52-week low/high is $0.54/$1.01.
Two Rivers Water & Farming Company (TURV)
TopPennyStockMovers, IRGnews Alert, and Stock Guru reported previously on Two Rivers Water & Farming Company (TURV), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Two Rivers Water & Farming Company is building a new water model for the arid regions of the southwestern U.S. The Company assembles its water assets through acquiring irrigated farmland with senior water rights because 85 percent of water rights in the arid southwest are owned by agricultural interests. Two Rivers transforms the value of its water rights and farmland by continually developing operations, which produce higher revenues and better profit margins. The Company is based in Denver, Colorado.
Two Rivers' present farm operations convert feed crop farmland into fruit and vegetable crop production in Pueblo County, Colorado. Two Rivers is providing greenhouses and processing facilities for licensed marijuana growers in Colorado on land with water rights not used for fruit and vegetable crop production. Additionally, the Company develops Metropolitan Districts to serve underserved communities in rural areas in which Two Rivers' farmland and water rights are situated.
Regarding Farming, Two Rivers’ produce sells to national accounts via its wholly-owned subsidiary Dionisio Farms & Produce. Pertaining to Water, Two Rivers owns a portfolio of water rights in the Arkansas River Basin in Colorado, obtained in connection with its purchases of irrigated farmland. Its water rights give it the ability to divert stream flow, operate storage reservoirs, pump ground water and augment depletions of water taken out of priority. Two Rivers also pumps water from the Arkansas River alluvium in addition to stream flow that it diverts from the Arkansas River and its tributaries.
The Company’s subsidiary is GrowCo, Inc. It was established in May of 2014 to construct greenhouses and processing facilities for lease to licensed marijuana growers in the State of Colorado. GrowCo, via its subsidiaries, combines proprietary greenhouse technology with the water, land, as well as capital to build state-of-the-art greenhouse facilities for licensed marijuana growers.
GrowCo is planning to file for an initial public offering (IPO) of its common stock soon after independent lessees have demonstrated marijuana growing results at each of GrowCo's first four grow facilities. At present, GrowCo is targeting the filing for the middle of 2016. This is subject to market and general economic conditions, and compliance with applicable securities laws.
GrowCo expects to complete construction of the greenhouse by next month. The design of the greenhouse is to have 90,000 square feet of growing space and 15,000 square feet of warehouse and processing space. The chief focus of the greenhouse facility will be to grow marijuana from which oils and other by-products can be extracted and utilized for marijuana-infused products. It is targeting the construction, through other subsidiaries, of three additional greenhouse facilities in Colorado this year.
Last month, Two Rivers Water & Farming announced that the Company’s Shareholders’ will earn 2,500,000 GrowCo, Inc. dividend shares. The Company announced that the second of four dividend record dates was scheduled to occur on April 1, 2015. Two Rivers has deposited and will dividend 10,000,000 GrowCo shares in an irrevocable trust. The distributions (in installments of 2,500,000) would be distributed, when registered, to shareholders of record of Two Rivers' common stock as of January 1, 2015, April 1, 2015, July 1, 2015 and October 1, 2015.
Two Rivers Water & Farming Company (TURV), closed Tuesday's trading session at $0.501, up 0.20%, on 5,655 volume with 8 trades. The average volume for the last 60 days is 17,392 and the stock's 52-week low/high is $0.4427/$1.46.
International Stem Cell Corp. (ISCO)
The QualityStocks Daily Newsletter would like to spotlight International Stem Cell Corp. (ISCO). Today, International Stem Cell Corp. closed trading at $0.063, up 1.45%, on 1,935,465 volume with 151 trades. The stock’s average daily volume over the past 60 days is 690,467, and its 52-week low/high is $0.045/$0.19.
International Stem Cell Corp. announced today that the company has published the results of two proof of concept studies that demonstrate the safety and efficacy of the company's readily expandable stem cell derived treatment of Parkinson's disease in both non-human primate and rodent animal models. The two studies demonstrated the safety and efficacy of transplanting human parthenogenetic neural stem cells (hpNSC) into animals with induced Parkinson's disease symptoms. No deformations, tumors or involuntary muscle movements (dyskinesia) developed. The studies further show that transplants of human parthenogenetic neural stem cells led to improvement of dopamine levels and increased cytokine levels.
International Stem Cell Corp. (ISCO) specializes in the therapeutic applications of human stem cells and the development and commercialization of cell-based biomedical products. The company was the first to develop and perfect a new class of human stem cells called parthenogenetic stem cells, created from unfertilized human eggs. ISCO has a strong patent portfolio offering clean intellectual property and freedom to operate. The company’s stem cells present superior immune matching capabilities and can be used in millions of people regardless of sex or racial background, with minimal expectation of immune rejection after transplantation.
The company’s human stem cells have been shown to be as pluripotent as embryonic stem cells, however their creation does not involve the destruction of a viable human embryo, which effectively sidesteps the controversy and ethical dilemmas associated with the use of human embryonic stem cells. In contrast to induced pluripotent stem cells, ISCO’s stem cells do not involve manipulation of cells’ genome thereby avoiding potential safety and regulatory obstacles in clinical applications.
The company's scientists are currently focused on using its stem cells to treat severe unmet medical needs of the central nervous system (Parkinson’s disease), the liver and the eye, where cell therapy has been clinically proven but is limited due to the unavailability of safe human cells. Once the technology has been clinically validated there are an essentially unlimited number of potential applications. Because of their immune-matching ability a relatively small number of these stem cell lines could offer the potential of producing the first true stem cell bank as a means of serving populations of different immune types across the globe.
In addition to its therapeutic focus, ISCO also provides a growing revenue stream through two wholly owned subsidiaries. Lifeline Cell Technology specializes in producing primary human cells and growth media for biological research, and Lifeline Skin Care, the company manufactures and markets advanced anti-aging skincare products utilizing the company’s expertise in stem cell biology. Disclaimer
International Stem Cell Corp. Company Blog
International Stem Cell Corp. News:
International Stem Cell Corporation Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
International Stem Cell Corporation Presents Data From Parkinson's Disease Program at AAN Annual Meeting
International Stem Cell Corporation Demonstrates Reversal of Neurological Stroke Symptoms Using Neural Stem Cells
Zenosense, Inc. (ZENO)
The QualityStocks Daily Newsletter would like to spotlight Zenosense, Inc. (ZENO). Today, Zenosense, Inc. closed trading at $0.1708, up 13.64%, on 142,960 volume with 37 trades. The stock’s average daily volume over the past 60 days is 28,995, and its 52-week low/high is $0.13/$0.95.
Zenosense, Inc. (ZENO) is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
Early detection of MRSA and HAIs in general is vital. Recent studies suggest that implementing prevention practices can lead to up to a 70 percent reduction in certain HAIs with a financial benefit of using these prevention practices estimated to be as high as $25.0 billion to $31.5 billion in medical cost savings in the United States alone (according to a report by the Centers for Disease Control and Prevention, part of the US Department of Health and Human Sciences). Currently, no cost effective early detection device is available.
The Zenosense MRSA detection device is expected to act like a “smoke detector” for MRSA; designed to detect MRSA in the environment or infected patient, even before a patient demonstrates any obvious symptoms, satisfying this huge unmet need.
Zenosense has an agreement with leading European sensor developer Sgenia Group, which is developing such a device exclusively for Zenosense through their subsidiary Zenon Biosystem. The estimated manufacturing cost per device is under $100 USD and possibly as low as $50 USD. The Zenosense device, utilizing established Sgenia programming and patent-pending hardware, utilizes a single sensor to perform an infinite number of scans, creating tens of thousands of "virtual sensors". The low cost and compact design of the Zenosense device, if successfully developed, would make it possible to be worn by individuals, as well as placed in numerous sensitive areas in the healthcare setting.
Zenosense has a streamlined management team experienced in high-level marketing in the medical sector, supported by the outsourced Zenon Biosystem scientific/development team of qualified personnel with extensive knowledge and experience in the development of sensors. Both of these teams will fuse together through a high level advisory board of experienced professionals. A cost-effective Zenosense MRSA detection device, once developed, is expected to be in high demand, driven by patient safety, cost and insurance considerations. Disclaimer
Zenosense, Inc. Company Blog
Zenosense, Inc. News:
Zenosense, Inc. - Hospital Collaboration - 400 Person Lung Cancer Detection Trial
Zenosense, Inc.; Stock Now DTC DWAC/FAST Eligible
Zenosense, Inc. Reports Manufacturing of Pre-Commercial Lung Cancer Detection Device
IFAN Financial, Inc. (IFAN)
The QualityStocks Daily Newsletter would like to spotlight IFAN Financial, Inc. (IFAN). Today, IFAN Financial, Inc. closed trading at $0.1805, up 2.56%, on 914,173 volume with 148 trades. The stock’s average daily volume over the past 60 days is 362,961, and its 52-week low/high is $0.0114/$1.01.
IFAN Financial, Inc. (IFAN) and its wholly owned subsidiaries, iPIN Technologies and Mobicash America, are engaged in the design, development and distribution of software that enhances and enables mobile payments. The San Diego-based company has a growing portfolio of solutions, including the ability to use a debit card and corresponding PIN number while purchasing online via mobile phone, tablet, or computer and peer-to-peer cash transfers.
Keeping pace with the evolution of the information and communication (ICT) market, iPIN Technologies intends to provide a range of processing services for the industry’s future devices. The company is currently developing a new method of online selling through debit card payments and processing. iPIN technology attaches to any smartphone through the headphone jack and converts the device into a consumer PIN debit, same-as-cash payment solution. Using the iPIN Debit app, transactions are processed through the private and secure iPIN Technologies Network.
Mobicash America is an early-stage technology company that develops mobile payment solutions. The company’s platform product, Quidme, utilizes the text messaging function of a mobile phone, allowing the technology to operate on almost any phone or network, with or without data service. The functionality of the Quidme platform allows users to pay bills, purchase goods and services, and to send money to friends and relatives located locally or internationally via simple text message.
IFAN Financial continues to explore opportunities to expand its product portfolio to meet the growing demands for consumer/merchant convenience, speed and security within the mobile commerce market. Products in development will combine the functionality of social media, e-commerce and banking with the broader conveniences of the mobile environment. Disclaimer
IFAN Financial, Inc. Company Blog
IFAN Financial, Inc. News:
IFAN Financial, Inc. (IFAN) Expands Board of Directors With Addition of Technology Venture Veteran
IFAN Financial Applauds Facebook's Move Into the Mobile Payments Industry, Foresees Ancillary Opportunities
IFAN Financial Begins Beta Testing With Nation's Largest Debit Card Acquiring Processor
Save The World Air, Inc. (ZERO)
The QualityStocks Daily Newsletter would like to spotlight Save The World Air, Inc. (ZERO). Today, Save The World Air, Inc. closed trading at $0.431, up 0.23%, on 122,058 volume with 34 trades. The stock’s average daily volume over the past 60 days is 116,530, and its 52-week low/high is $0.3401/$0.86.
Save The World Air, Inc. (ZERO) (“STWA”) provides the global energy industry with patent-protected industrial equipment designed to deliver measurable performance improvements to crude oil pipelines. Developed in partnership with leading crude oil production and transportation entities, STWA’s high-value solutions address the enormous capacity inadequacies of domestic and overseas pipeline infrastructures that were designed and constructed prior to the current worldwide surge in oil production.
In support of our clients’ commitment to the responsible sourcing of energy and environmental stewardship, STWA combines scientific research with inventive problem solving to provide energy efficiency ‘clean tech’ solutions to bring new efficiencies and lower operational costs to the upstream, midstream and gathering sectors. STWA’s flagship product, AOT (Applied Oil Technology) improves the economics of transporting crude oil by reducing the viscosity of oil in pipelines. Once deployed on pipeline pumping stations, production and transportation companies benefit from the safer, more cost-effective delivery of greater volumes of oil while reducing energy consumption at pumping stations and lowering CO2 emissions.
The AOT technology is the result of years of research conducted at Temple University (Philadelphia, Penn.) and is the world’s first ASME-certified industrial hardware to use the principles of electrorheology, the study of applying non-uniform electrical fields to change the mechanical behavior of fluids, to significantly reduce the viscosity of crude oil within pipelines during maximum flow conditions. Field tested by the U.S. Department of Energy, independent testing laboratories such as ATS RheoSystems and fabricated to exacting industry standards by STWA’s supply chain partners, the efficacy of AOT to increase flow rates, prevent bottlenecks, reduce pump station power consumption, enhance pipeline integrity and optimize flow assurance has been proven repeatedly in the lab and on a 300,000 barrel per day pipeline.
STWA is also commercializing STWA Joule Heat, an energy-efficient technology for heating crude oil in pipelines to improve flow. Unlike traditional trace heating systems which generate heat via a resistive trace heating element which transfers energy into the oil, the STWA solution applies an electrical field directly to oil, generating heat within the flow itself. The result is optimal heat conductivity and performance with less power and in a smaller form factor.
Guided by a dynamic management team led by Greggory Bigger, Chief Executive Officer, Chairman and a strong independent board of directors of energy industry veterans, STWA is a revenue generating company with a solid cash position, clean balance sheet and a proven ability to develop and deliver industrial-grade equipment that support the company’s mission and enhance shareholder value. As the exclusive licensee of oil viscosity reduction processes developed at Temple University and owner of 48 worldwide patents related to the use of electricity to change the mechanical behavior of oil and liquid natural gas, STWA is well-positioned to capitalize on the explosive growth opportunities in the global crude oil production and transportation sector. More information is available at: www.stwa.com. Disclaimer
Save The World Air, Inc. Company Blog
Save The World Air, Inc. News:
STWA Selected as a Finalist for the 2015 Global Petroleum Show Awards
STWA Reports 2014 Year-End Financial Results and Provides Operational Update
STWA Sets Date for Its Year-End 2014 Earnings Results Release and Conference Call
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $9.99, even for the day. The stock’s average daily volume over the past 60 days is 646, and its 52-week low/high is $3.16/$15.00.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate, has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
Dr. Gerard Sanacora Joins VistaGen's Clinical and Scientific Advisory Board
VistaGen Signs Letter of Intent With National Institute of Mental Health for NIH-Sponsored Phase 2 Clinical Study of AV-101 in Major Depressive Disorder
MIT Holding (MITD)
The QualityStocks Daily Newsletter would like to spotlight MIT Holding (MITD). Today, MIT Holding closed trading at $0.06 even for the day. The stock’s average daily volume over the past 60 days is 12,781, and its 52-week low/high is $0.032/$0.29.
MIT Holding (MITD), through its agents, facilitators and contractual obligations, offers professional outpatient medical care with ambulatory infusion therapies, home infusion services, and medical equipment delivery. The company is also pursuing government contacts to obtain approval to import pharmaceutical products into the Americas.
In support of these core services, MIT Holding provides expert legal, accounting, advisory and educational services to physicians, medical centers, hospitals, small and large businesses regarding the Affordable Care Act; offers travel and transportation services of medically challenged patients for medical needs and personal travel; and through its contracts is approved to, conduct and administer FDA clinical trials.
Collectively, these services contribute to MIT Holding’s strategy to provide custom prescription solutions in a variety of methods and generate multiple revenue streams. Following a successful reorganization initiative in January, 2014, MIT Holding is positioned to achieve 32% minimum net profits and has maintained profitability in its fiscal second and third quarters. This profitability validates the company’s business model and its approach to the evolving Affordable Health Care Act and its impact on the health services industry.
MIT Holding meets and/or exceeds major U.S. health insurance requirements and is therefore able to direct bill and receive payments from carriers on behalf of the patient its agents and its facilitators. This ability marks an important step in the company’s goal of developing the first-of-its-kind seamless transition for patient needs from hospital discharge to complete home recovery. This and other corporate initiatives are spearheaded by a management team committed to building shareholder value, revenues and corporate expansion while providing viable solutions to the perpetual changes in the health care sector. Disclaimer
MIT Holding Company Blog
MIT Holding News:
MIT Holding (MITD) Launches New Website with Investor Relations Suite
MIT Holding, Inc. Names Tommy J. Duncan as President
MIT Holding, Inc. (MITD) Announces Engagement of QualityStocks Investor Relations Services
Cleartronic, Inc. (CLRI)
The QualityStocks Daily Newsletter would like to spotlight Cleartronic, Inc. (CLRI). Today, Cleartronic, Inc. closed trading at $0.065, even for the day. The stock’s average daily volume over the past 60 days is 3,421, and its 52-week low/high is $0.04/$0.5499.
Cleartronic, Inc. (CLRI) is a technology holding company that creates and acquires operating subsidiaries to develop, manufacture and sell products, services and integrated systems to government agencies and business enterprises.
VoiceInterop, Inc., a wholly owned subsidiary, is a provider of patented IP communication gateways and communication software. Its gateways are marketed worldwide direct to customers as well as through a network of value added resellers. VoiceInterop has also developed an interoperable communication solution for use by airports. The company markets, installs and supports this interoperability solution directly to airports. International airports currently using the VoiceInterop communication solution include Dulles, Reagan, Omaha, Cincinnati, Green Bay and West Palm Beach.
A recent license agreement provides Cleartronic with the right to market Collabria LLC’s revolutionary ReadyOp™ command, control and communication platform. ReadyOp is a web-based application that integrates multiple databases and a robust communications platform supporting day-to-day activities for planning and managing small- and large-scale events. ReadyOp is designed for fast, efficient access to information and for communication with multiple persons, groups and agencies. ReadyOp is currently being used by numerous federal, state and local government agencies and private enterprises.
Backed by a management team committed to growing its business and finding ways to create value for shareholders, Cleartronic is well-positioned to grow in a broad array of markets. The company has a solid business plan in place that maximizes available resources for accelerated growth and has proven its ability to identify strong business opportunities. Disclaimer
Cleartronic, Inc. Company Blog
Cleartronic, Inc. News:
Cleartronic, Inc. (CLRI) Adds Shareholder Value With Cancellation of Two Billion Shares of Common Stock Held by CEO
Cleartronic Announces Expanded License Agreement With Collabria LLC
Cleartronic Appoints Two New Members to Board of Directors
Today's Top 3
INO.com Market Report
Top Stock Picks
Wall Street Resources
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Car Monkeys Group (CKMY) Announces Engagement of QualityStocks Investor Relations Services
- Cleartronic, Inc. (CLRI) Adds Shareholder Value With Cancellation of Two Billion Shares of Common Stock Held by CEO
- Consorteum Holdings, Inc. (CSRH) Signs License Agreement With NYG Holdings
- Dominovas Energy Corp. (DNRG) Key Management Featured in Exclusive QualityStocks Interview
- Falcon Crest Energy (FCEN) Acquires Remaining Working Interest in Rocky Ford Field
- IFAN Financial, Inc. (IFAN) Expands Board of Directors With Addition of Technology Venture Veteran
- International Stem Cell Corp. (ISCO) Publishes Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
- Inventergy Global, Inc. (INVT) Announces $2.15 Million Common Stock Financing to Accelerate Licensing Operations
- MIT Holding, Inc. (MITD) Launches New Website with Investor Relations Suite
- Mobile Lads Corp. (MOBO) Begins Operating And Buys Control Of North American Shopping Network Simbadeals.com From DoMark International
- One World Holdings, Inc. (OWOO) Raises Capital to Fund National Expansion and Convertible Note Elimination
- Pure Hospitality Solutions, Inc. (PNOW) National Tourism Center Of Costa Rica Gives Pure Opportunity
- Save The World Air, Inc. (ZERO) Reports 2014 Year-End Financial Results and Provides Operational Update
- Sibling Group Holdings, Inc. (SIBE) Urban Planet Mobile Deepens Strategic Partnership With Imagine Easy Solutions and EasyBib; UPMs Writing Planet Essay Scoring Solution to Be Offered Across All Imagine Easy Citation Websites Worldwide
- Sparta Commercial Services, Inc. (SRCO) iMobileApp's Customer Base Continues to Diversify
- VistaGen Therapeutics, Inc. (VSTA) and NIH Sign Agreement for NIH-Sponsored Phase 2 Study of Orally-Active AV-101 in Major Depressive Disorder
- Well Power Inc. (WPWR) Appoints Professional Engineer, Oil & Gas Veteran to Board of Directors
- Zenosense, Inc. (ZENO) Hospital Collaboration - 400 Person Lung Cancer Detection Trial